0{{current_slide_index}} | 0{{total_slide_count}}
Past transaction from cutting edge academic research to successful IPO on the London Stock Exchange:
We help finance clinical research and development in the following indications
Alzheimer
Best-in-class single clinical phase III data, including mild & moderate patients. Clearly superior to Biogen and Eli Lilly’s approved drugs. Licensing agreement pending.
Thrombosis and stroke prevention
Beginning of the phase III.
Imunno-modulatory platform.
Portfolio of PDI inhibitors.
Mutliple Sclerosis
Best-in-class single clinical phase III data. At least at parity with Roche’s Ocrevus, the current gold standard, but with different mechanism of action. Ideal combo
Amyotrophic Lateral Sclerosis
Best-in-class single clinical Phase III data. Superior to Amylyx, Ederavone. Waiting for conditional approval by Health Canada and FDA
HPV / HIV / Dengue Fever / West Nile / Malaria
Next generation vaccine & immunotherapy platform from Pasteur
Multiple Phase 1/2 with 100% positive responses
Complex Polyp Surgery / GI
Next generation upper and lower GI diagnostic & surgical platform. Natural takeover by big MedTech interested to expand and improve their GI platform (Medtronic, J&J, Olympus, Boston S)
Sickle Cell Anemia
Phase IIb with group of university hospitals
Inherited disorder modi-cation of red blood cells
5-10% prevalence in MENA region. 350K new patients/yr
Alternative to $2m stem cell treatment
Stroke Detection
Immediate and on-location blood test analysis, reducing critical triage time at hospital. Natural takeover by major diagnostic platform (Abbott, Roche)
Emerging evidence of potential brake through in anti-cancer treats
Brain tumor
Beginning of the phase III. Venous thromboembolism (VTE) prevention in cancer (Phase III). Reduce cancer metastasis
Lung cancer
Beginning of the phase III. Venous thromboembolism (VTE) prevention in cancer (Phase III). Reduce cancer metastasis
Ovarian cancer
Beginning of the phase III. Venous thromboembolism (VTE) prevention in cancer (Phase III). Reduce cancer metastasis
Pancreatic cancer
Beginning of the phase III. Venous thromboembolism (VTE) prevention in cancer (Phase III). Reduce cancer metastasis
PHILANTHROPY
SUPPORTED MUSICIANS
Contacts
Philippe Froehlicher
+30 years of experience in portfolio management and capital markets. +10 years of experience in private equity.
In 2009, he co-founded FGP Capital. His responsibilities include the strategic development of the firm. Philippe oversees asset allocation and investment decisions. Prior to 2009, Philippe ran discretionary global mandates for HNWI at Pictet & Cie since 1998.
Philippe has studied with world famous professors in corporate strategy, including Michael Porter (Harvard) and Klaus Schwab (World Economic Forum). He holds a Master in Business Administration & Economics from the University of Geneva, where he specialized in finance and corporate strategy.
Richard Ormond
+35 years of investment experience in fund, portfolio and client management. +10 years of experience in private equity
His expertise has expanded from traditional investments to private equity and debt investments in growth capital for life science, technology and consumer companies.
Prior to joining the Group in 2012, Richard spent 22 years as client and fund manager (Small Caps and Emerging Markets) with Pictet & Cie. Richard holds a Master in Business & Management and completed his studies with a postgraduate Diploma in Economics & Finance from the University of Geneva.
© FGP CAPITAL
Geneva, Switzerland
7, Rue des Alpes
1201 Genève
Switzerland
info@fgpcapital.com
+41 (0) 22 753 53 53